Indrayani Biotech Defaults on Loans, Faces SARFAESI Action from Hinduja Leyland Finance

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Indrayani Biotech Defaults on Loans, Faces SARFAESI Action from Hinduja Leyland Finance
Overview

Indrayani Biotech Limited has been issued a SARFAESI demand notice by Hinduja Leyland Finance Limited, classifying its term loans as Non-Performing Assets (NPA). The company failed to meet principal and interest payments, defaulting on ₹6.46 crore directly and ₹19.12 crore as co-borrower. Total financial indebtedness stands at ₹54.48 crore. The company is evaluating the notice to regularize its loan accounts.

Indrayani Biotech Faces SARFAESI Notice Amid Loan Defaults

Indrayani Biotech Limited is in deep financial distress, having received a SARFAESI demand notice from Hinduja Leyland Finance Limited on January 30, 2026. This action follows the classification of the company's term loans as a Non-Performing Asset (NPA) due to a failure to meet principal and interest installment payments.

📉 The Financial Deep Dive

  • The Numbers: The company reported a direct outstanding amount of ₹6,46,46,764.02 to Hinduja Leyland Finance. Additionally, as a co-borrower for seven other entities, Indrayani Biotech holds an outstanding debt of ₹19,12,40,118.28. The default date for these obligations was recorded as December 26, 2025.
  • Total Indebtedness: Indrayani Biotech's total borrowings from banks and financial institutions aggregate to ₹41,00,01,653/-. Including short-term and long-term debt, the company's total financial indebtedness stands at a substantial ₹54,48,47,022/-.
  • The Quality: The classification of loans as NPA signals severe financial strain, indicating that the company is unable to service its debt obligations. The SARFAESI Act empowers lenders to recover debts by taking possession of assets, initiating potential asset seizure for Indrayani Biotech.

🚩 Risks & Outlook

  • Specific Risks: The primary risk is the potential seizure of company assets by Hinduja Leyland Finance under the SARFAESI Act. Furthermore, the NPA classification severely impacts the company's credit rating, making it difficult to secure future financing and potentially triggering covenants on existing debt. Regulatory scrutiny is also expected to intensify.
  • The Forward View: Investors should closely monitor Indrayani Biotech's actions following its evaluation of the demand notice. The company's ability to negotiate a resolution, regularize loan accounts, or face the consequences of asset recovery will be critical. The market will be looking for transparency and a viable plan to manage its significant debt burden.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.